ADCY8
-
Official Full Name
adenylate cyclase 8 (brain)
-
Overview
Adenylate cyclase is a membrane bound enzyme that catalyses the formation of cyclic AMP from ATP. The enzymatic;activity is under the control of several hormones, and different polypeptides participate in the transduction of the;signal from the receptor to the catalytic moiety. Stimulatory or inhibitory receptors (Rs and Ri) interact with G;proteins (Gs and Gi) that exhibit GTPase activity and they modulate the activity of the catalytic subunit of the;adenylyl cyclase. -
Synonyms
ADCY8; adenylate cyclase 8 (brain); ADCY3; adenylate cyclase type 8; AC8; HBAC1; adenylyl cyclase 8; ATP pyrophosphate-lyase 8; adenylyl cyclase-8, brain; adenylate cyclase type VIII; ca(2+)/calmodulin-activated adenylyl cyclase;
- Recombinant Proteins
- Cell & Tissue Lysates
- Protein Pre-coupled Magnetic Beads
- Human
- Mouse
- Rat
- Zebrafish
- E.coli
- E.Coli or Yeast
- HEK293
- Mammalian Cell
- Wheat Germ
- GST
- His
- Fc
- Avi
- Non
- Involved Pathway
- Protein Function
- Interacting Protein
- ADCY8 Related Signal Pathway
ADCY8 involved in several pathways and played different roles in them. We selected most pathways ADCY8 participated on our site, such as Activation of GABAB receptors, Activation of NMDA receptor upon glutamate binding and postsynaptic events, Adenylate cyclase activating pathway, which may be useful for your reference. Also, other proteins which involved in the same pathway with ADCY8 were listed below. Creative BioMart supplied nearly all the proteins listed, you can search them on our site.
Pathway Name | Pathway Related Protein |
---|---|
Activation of GABAB receptors | ADCY3;KCNJ6;GNB3B;KCNJ4;KCNJ9;ADCY6;ADCY1;KCNJ10;KCNJ3 |
Activation of NMDA receptor upon glutamate binding and postsynaptic events | CREB1;ADCY3;ADCY1;CREB1B;AKAP9;DLG4;PDPK1A;NETO2;NEFLB |
Adenylate cyclase activating pathway | ADCY7;ADCY9;ADCY8;ADCY3;ADCY6;ADCY1 |
Adenylate cyclase inhibitory pathway | ADCY1;ADCY3;ADCY7;ADCY8;ADCY9;ADCY6 |
Adrenergic signaling in cardiomyocytes | KCNQ1;CACNB2;SLC8A1;CALM1B;TNNI3;TNNC1A;ATP1B1A;ATP2B3B;CACNA2D4 |
Aldosterone synthesis and secretion | ITPR3;DAGLB;CAMK4;LDLR;CAMK1G;CYP21A1;CACNA1G;KCNK9;CAMK2A |
Aquaporin-mediated transport | MIPB;AQP3A;AQP1A.1;AQP8A.1;ADCY8;ADCY7;GNB3B;ADCY6;MYO5B |
Bile secretion | SLCO1A5;NCEH1;SLCO1B2;PRKACA;ATP1B1;AQP8;SCTR;SCARB1;SLC22A1 |
ADCY8 has several biochemical functions, for example, ATP binding, adenylate cyclase activity, calcium- and calmodulin-responsive adenylate cyclase activity. Some of the functions are cooperated with other proteins, some of the functions could acted by ADCY8 itself. We selected most functions ADCY8 had, and list some proteins which have the same functions with ADCY8. You can find most of the proteins on our site.
Function | Related Protein |
---|---|
ATP binding | KIF16B;CDC42BPB;SMC1AL;MYO5A;PRKACBA;CMPK2;LYN;AKT3A;SYN2 |
adenylate cyclase activity | ADCY7;ADCY6;ADCY9;ADCY1;ADCY1A;ADCY1B;ADCY3;ADCY2B;Adcy4 |
calcium- and calmodulin-responsive adenylate cyclase activity | ADCY1;ADCY6;ADCY8;ADCY3 |
metal ion binding | OASL2;ZNHIT2;SMAP1;ITPA;SP4;ZC3H15;ZFP828;ITGA7;BCL6AB |
ADCY8 has direct interactions with proteins and molecules. Those interactions were detected by several methods such as yeast two hybrid, co-IP, pull-down and so on. We selected proteins and molecules interacted with ADCY8 here. Most of them are supplied by our site. Hope this information will be useful for your research of ADCY8.
CFTR
- Reviews
- Q&As
Q&As (14)
Ask a questionYes, targeting ADCY8 protein may have therapeutic potential in other diseases. For example, modulating ADCY8 activity may be beneficial in the treatment of neurological disorders such as Parkinson's disease and schizophrenia, as well as in obesity and certain cancers.
There are currently no drugs available that specifically target ADCY8 protein. However, drugs that affect the cAMP-PKA signaling pathway, such as glucagon-like peptide-1 (GLP-1) agonists used in the treatment of type 2 diabetes, indirectly affect ADCY8 activity.
Yes, targeting ADCY8 protein may be a potential therapeutic strategy for diabetes. Modulating ADCY8 activity can regulate insulin secretion and improve glucose homeostasis. However, further research is needed to determine the safety and efficacy of modulating ADCY8 in humans.
Developing drugs that specifically target ADCY8 protein can be challenging due to its complex regulation and interaction with other signaling pathways. Additionally, targeting ADCY8 may affect other physiological processes that could lead to unwanted side effects. Further research is needed to fully understand ADCY8's role in various diseases and to develop safe and effective therapeutics.
The potential side effects of targeting ADCY8 protein are not well known as this is an emerging area of research. However, as with any drug targeting a specific protein, potential side effects could include off-target effects, changes in related signaling pathways, and potential toxicity.
ADCY8 is being explored as a potential target in obesity treatment due to its role in regulating energy metabolism and appetite control. Modulating ADCY8 activity may help to improve energy expenditure and reduce food intake, leading to weight loss.
Measuring ADCY8 protein levels alone may not be sufficient for diagnosis of diseases. However, measuring ADCY8 activity or levels in conjunction with other diagnostic tests may provide additional information for disease diagnosis, prognosis, and treatment.
ADCY8 is being studied as a potential therapeutic target in neurological disorders, such as Parkinson's disease and schizophrenia, due to its role in neurotransmitter signaling and neuronal function. Modulating ADCY8 activity may help to improve synaptic plasticity and reduce cognitive impairment in these disorders.
There are currently no drugs that specifically target ADCY8 protein. However, compounds that modulate ADCY8 activity are being developed and tested for their therapeutic potential.
ADCY8 protein is regulated by a variety of factors, including hormonal and neural signals. For example, glucagon-like peptide-1 (GLP-1) and glucose signal through G protein-coupled receptors to activate ADCY8 and stimulate insulin secretion. Other factors, such as dopamine and calcium ions, can also modulate ADCY8 activity.
It is currently not possible to supplement ADCY8 protein for therapeutic purposes. However, the development of ADCY8 agonists or inhibitors may help to modulate ADCY8 activity for therapeutic benefit.
ADCY8 protein is not typically used as a direct diagnostic tool. However, measuring ADCY8 expression levels or genetic variants associated with ADCY8 may be useful in predicting disease outcomes and identifying patients who may benefit from certain treatments.
Yes, several genetic variants in the ADCY8 gene have been associated with various diseases and traits, including obesity, diabetes, and schizophrenia. These variants can affect ADCY8 expression levels, activity, and function, leading to altered signaling pathways.
ADCY8 protein is being studied in various research settings, including preclinical studies in animal models and in vitro studies to understand its role in disease and potential therapeutic targets. Clinical trials may also be conducted in the future to test the efficacy and safety of drugs targeting ADCY8 in humans.
Ask a Question for All ADCY8 Products
Required fields are marked with *
My Review for All ADCY8 Products
Required fields are marked with *